ITGAL Antikörper (FITC)
Kurzübersicht für ITGAL Antikörper (FITC) (ABIN457347)
Target
Alle ITGAL Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Verwendungszweck
- Anti-Ms CD11a FITC
-
Kreuzreaktivität (Details)
- Mouse
-
Produktmerkmale
- The rat monoclonal antibody M17/4 reacts with an extracellular epitope of CD11a (alpha-subunit of murine LFA-1), a 180 kDa type I transmembrane glycoprotein expressed on B and T lymphocytes, monocytes, macrophages, neutrophils, basophils and eosinophils.
-
Aufreinigung
- Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
-
Immunogen
- C57BL/6 mouse splenic secondary cytotoxic T lymphocytes
-
Isotyp
- IgG2a
-
-
-
-
Applikationshinweise
- Flow cytometry: Recommended dilution: 1-2 μg/mL.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.5 mg/mL
-
Buffer
- Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Do not freeze,Protect from prolonged exposure to light
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
-
-
-
: "Soluble MHC-peptide complexes containing long rigid linkers abolish CTL-mediated cytotoxicity." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 176, Issue 6, pp. 3356-65, (2006) (PubMed).
: "The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo." in: Respiratory research, Vol. 6, pp. 70, (2005) (PubMed).
: "Adhesion molecule-dependent mechanisms regulate the rate of macrophage clearance during the resolution of peritoneal inflammation." in: The Journal of experimental medicine, Vol. 196, Issue 11, pp. 1515-21, (2002) (PubMed).
: "In situ demonstration of intraepithelial lymphocyte adhesion to villus microvessels of the small intestine." in: International immunology, Vol. 13, Issue 9, pp. 1165-74, (2001) (PubMed).
: "Synergistic mobilization of hemopoietic progenitor cells using concurrent beta1 and beta2 integrin blockade or beta2-deficient mice." in: Blood, Vol. 97, Issue 5, pp. 1282-8, (2001) (PubMed).
: "The accessory function of murine intercellular adhesion molecule-1 in T lymphocyte activation. Contributions of adhesion and co-activation." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 146, Issue 6, pp. 1773-82, (1991) (PubMed).
: "Antigens involved in mouse cytolytic T-lymphocyte (CTL)-mediated killing: functional screening and topographic relationship." in: Cellular immunology, Vol. 73, Issue 1, pp. 1-11, (1983) (PubMed).
-
: "Soluble MHC-peptide complexes containing long rigid linkers abolish CTL-mediated cytotoxicity." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 176, Issue 6, pp. 3356-65, (2006) (PubMed).
-
- ITGAL (Integrin alpha-L (ITGAL))
-
Andere Bezeichnung
- CD11a
-
Hintergrund
- Integrin subunit alpha L,CD11a (LFA-1 alpha) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the alphaLbeta2 integrin. CD11a is implicated in activation of LFA-1 complex. LFA-1 is expressed on the plasma membrane of leukocytes in a low-affinity conformation. Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of LFA-1 to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3. LFA-1 is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions. Blocking of LFA-1 function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases. For example, humanized anti-LFA-1 antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation, binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity.,LFA-1, LFA1A, ITGAL
-
Gen-ID
- 16408
-
UniProt
- E9Q5M7
-
Pathways
- Activated T Cell Proliferation, Integrin Complex
Target
-